ethyl-3-{[(allyloxy)carbonyl]amino}-3-(3-{[(3-nitrophenyl)sulfonyl]amino}-phenyl)propanoate | 283613-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-3-{[(allyloxy)carbonyl]amino}-3-(3-{[(3-nitrophenyl)sulfonyl]amino}-phenyl)propanoate
• 英文别名: ethyl 3-allyloxycarbonylamino-3-(3-[3-nitrophenylsulphonylamino]-phenyl)-propionate；ethyl 3-[3-[(3-nitrophenyl)sulfonylamino]phenyl]-3-(prop-2-enoxycarbonylamino)propanoate
• CAS: 283613-57-0
• 化学式: C₂₁H₂₃N₃O₈S
• 分子量: 477.495
• InChiKey: XTPYAGXLXFYVHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  33
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  165
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  ethyl-3-{[(allyloxy)carbonyl]amino}-3-(3-{[(3-nitrophenyl)sulfonyl]amino}-phenyl)propanoate 在 乙醇 、 tin(ll) chloride 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 2.0h， 生成 ethyl-3-{[(allyloxy)carbonyl]amino}-3-(3-{[(3-aminophenyl)sulfonyl]amino}phenyl)propanoate
  参考文献：
  名称：

  Integrin-Mediated drug targeting

  摘要：

  本发明涉及细胞毒药物，由于与αvβ3整合素拮抗剂通过优选连接单元的连接而具有肿瘤特异性作用。优选连接单元保证细胞毒药物和αvβ3整合素拮抗剂的结合物在血清中的稳定性，同时由于它们在肿瘤细胞内的酶解或水解性而释放细胞毒药物，从而实现所需的细胞内作用。

  公开号：

  US20060189544A1
• 作为产物：
  描述：

  ethyl 3-{[(allyloxy)carbonyl]amino}-3-(3-aminophenyl)propanoate 、 3-硝基苯磺酰氯 在 盐酸 、 二氯甲烷 、 magnesium sulfate 作用下， 以 吡啶 为溶剂， 反应 2.0h， 以16.8 g of product were obtained的产率得到ethyl-3-{[(allyloxy)carbonyl]amino}-3-(3-{[(3-nitrophenyl)sulfonyl]amino}-phenyl)propanoate
  参考文献：
  名称：

  Integrin-Mediated drug targeting

  摘要：

  本发明涉及通过首选连接单元与αvβ3整合素拮抗剂连接而具有肿瘤特异性作用的细胞毒素。首选连接单元保证细胞毒素和αvβ3整合素拮抗剂的结合物在血清中的稳定性，同时由于它们的酶促或水解性可被肿瘤细胞内释放，从而达到所需的细胞内作用。

  公开号：

  US20060189544A1

文献信息

• Cytostatic-integrin conjugates having specifically cleavable linking units
  申请人：——

  公开号：US20020183256A1

  公开（公告）日：2002-12-05

  The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to &agr; v &bgr; 3 integrin antagonists via preferred linking units which can be selevtively cleaved by enzymes such as metallo matrixproteases (MMPs), i.e. by enzymes which can especially be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and &agr; v &bgr; 3 integrin antagonist and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

  该发明涉及细胞毒药物，由于与αvβ3整合素拮抗剂通过首选连接单元的连接而具有肿瘤特异性作用，这些连接单元可以被金属基质蛋白酶（MMPs）等酶选择性地裂解，即可以在肿瘤组织中特别发现的酶。首选连接单元保证了细胞毒药物和αvβ3整合素拮抗剂的结合物的血清稳定性，并同时由于其特异性酶解或水解可释放细胞毒药物而在肿瘤细胞内产生所需的细胞内作用。
• Novel cytostatic conjugates with integrin ligands
  申请人：——

  公开号：US20020193311A1

  公开（公告）日：2002-12-19

  The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to &agr; v &bgr; 3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and &agr; v &bgr; 3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

  本发明涉及细胞毒素，其通过与&agr;v&bgr;3整合素拮抗剂连接而具有肿瘤特异性作用，所述连接单元通过弹性蛋白酶选择性切割，即一种特别存在于肿瘤组织中的酶。所述优选连接单元提供了细胞毒素和&agr;v&bgr;3整合素拮抗剂的共轭物在生物液体中足够的稳定性，并且由于其特异性的酶解或水解可释放细胞毒素，从而在肿瘤细胞内产生所需的细胞内作用。
• Cytostatic conjugates with integrin ligands
  申请人：Bayer Akiengesellschaft

  公开号：US07304037B2

  公开（公告）日：2007-12-04

  The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumor tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and αvβ3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

  本发明涉及一种细胞毒素，通过与αvβ3整合素拮抗剂的偏好连接单元连接，从而具有肿瘤特异性作用，这些连接单元可以被弹性蛋白酶选择性地裂解，即一种特别存在于肿瘤组织中的酶。所述的偏好连接单元在生物体液中提供足够的细胞毒素和αvβ3整合素拮抗剂的结合稳定性，并且同时通过其特异性的酶促或水解裂解释放细胞毒素，从而实现所需的肿瘤细胞内作用。
• Integrin-mediated drug targeting
  申请人：Bayer Aktiengesellschaft

  公开号：US07220824B1

  公开（公告）日：2007-05-22

  The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.

  本发明涉及通过首选连接单元与αvβ3整合素拮抗剂连接而具有肿瘤特异性作用的细胞毒素。所述首选连接单元保证了细胞毒素与αvβ3整合素拮抗剂的共轭物在血清中的稳定性，同时在肿瘤细胞内具有所需的酶解或水解性，以释放细胞毒素。
• Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
  申请人：Bayer Aktiengesellschaft

  公开号：EP1219305A1

  公开（公告）日：2002-07-03

  The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units which can be selectively cleaved by enzymes such as metallo matrixproteases (MMPs), i.e. by enzymes which can especially be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

  本发明涉及一种细胞抑制剂，它通过优选的连接单元与αvβ3整合素拮抗剂连接，从而具有肿瘤特异性作用，这种连接单元可被金属基蛋白酶（MMPs）等酶选择性地裂解，即被特别存在于肿瘤组织中的酶裂解。优选的连接单元保证了细胞抑制剂和 αvβ3 整合素拮抗剂共轭物在血清中的稳定性，同时，由于其特定的酶或水解裂解能力，可释放出细胞抑制剂，从而在肿瘤细胞内发挥理想的细胞内作用。